{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T06:39:22Z","timestamp":1780555162462,"version":"3.54.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T00:00:00Z","timestamp":1754611200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T00:00:00Z","timestamp":1754611200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pulm Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Objective<\/jats:title>\n            <jats:p>To evaluate the efficacy and safety of inhaled ambroxol solution in improving sputum of lower respiratory tract infections (LRTIs) in children.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Study Design<\/jats:title>\n            <jats:p>This study was a randomized, double-blind, parallel-group, placebo-controlled, multicenter trial. The patients were administered inhaled ambroxol or a placebo twice a day for 7 days. And researchers collected efficacy and (or) safety indicators every day during the course.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>A total of 236 children were randomly assigned to receive ambroxol or placebo (1:1). At all visit points after the medication, the mean difference of cough score with the baseline between the two groups was statistically significant (P\u2009&lt;\u20090.05). Compared with the baseline, the phlegm-sound scores in the throat of the experimental group decreased more on the 1st, 2nd, and 3rd days after administration (P\u2009&lt;\u20090.05). But there was no difference in pulmonary rale scores. The occurrence of adverse events in the experimental group was lower (21.37% vs. 35.59%, P\u2009=\u20090.021), and the incidence of adverse reactions was similar between the two groups (2.56% vs. 5.08%, P\u2009=\u20090.499).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Inhaled ambroxol solution could improve the sticky sputum symptoms in children with LRTIs and is safe in clinical application. Further research is needed to confirm these findings.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Trial registration<\/jats:title>\n            <jats:p>The study was retrospectively registered on June 14, 2023, at <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"https:\/\/www.chictr.org.cn\/\" ext-link-type=\"uri\">https:\/\/www.chictr.org.cn\/<\/jats:ext-link> under the number ChiCTR2300072466.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s12890-025-03845-0","type":"journal-article","created":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T10:33:31Z","timestamp":1754649211000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and safety of inhaled ambroxol solution in improving sputum of lower respiratory tract infection in children: a multicenter, randomized, double-blind, placebo-controlled trial"],"prefix":"10.1186","volume":"25","author":[{"given":"Baoping","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunxiao","family":"Shang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huanji","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiying","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaoru","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enmei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunling","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,8]]},"reference":[{"issue":"2","key":"3845_CR1","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1034\/j.1399-3003.1999.14b35.x","volume":"14","author":"E Houtmeyers","year":"1999","unstructured":"Houtmeyers E, Gosselink R, Gayan-Ramirez G, Decramer M. Effects of drugs on mucus clearance. Eur Respir J. 1999;14(2):452\u201367.","journal-title":"Eur Respir J"},{"key":"3845_CR2","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.intimp.2016.02.004","volume":"33","author":"LT Ge","year":"2016","unstructured":"Ge LT, Liu YN, Lin XX, Shen HJ, Jia YL, Dong XW, et al. Inhalation of ambroxol inhibits cigarette smoke-induced acute lung injury in a mouse model by inhibiting the Erk pathway. Int Immunopharmacol. 2016;33:90\u20138.","journal-title":"Int Immunopharmacol"},{"issue":"6","key":"3845_CR3","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1165\/rcmb.2009-0348OC","volume":"43","author":"MM Myerburg","year":"2010","unstructured":"Myerburg MM, Harvey PR, Heidrich EM, Pilewski JM, Butterworth MB. Acute regulation of the epithelial sodium channel in airway epithelia by proteases and trafficking. Am J Respir Cell Mol Biol. 2010;43(6):712\u20139.","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"12","key":"3845_CR4","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1111\/j.2042-7158.1991.tb03191.x","volume":"43","author":"J Tamaoki","year":"1991","unstructured":"Tamaoki J, Chiyotani A, Yamauchi F, Takeuchi S, Takizawa T. Ambroxol inhibits Na\u2009+\u2009absorption by canine airway epithelial cells in culture. J Pharm Pharmacol. 1991;43(12):841\u20133.","journal-title":"J Pharm Pharmacol"},{"issue":"4","key":"3845_CR5","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1177\/039463201302600406","volume":"26","author":"DG Peroni","year":"2013","unstructured":"Peroni DG, Moser S, Gallo G, Pigozzi R, Tenero L, Zanoni L, et al. Ambroxol inhibits neutrophil respiratory burst activated by alpha chain integrin adhesion. Int J Immunopathol Pharmacol. 2013;26(4):883\u20137.","journal-title":"Int J Immunopathol Pharmacol"},{"issue":"1","key":"3845_CR6","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/s00134-003-2001-y","volume":"30","author":"X Su","year":"2004","unstructured":"Su X, Wang L, Song Y, Bai C. Inhibition of inflammatory responses by ambroxol, a mucolytic agent, in a murine model of acute lung injury induced by lipopolysaccharide. Intensive Care Med. 2004;30(1):133\u201340.","journal-title":"Intensive Care Med"},{"issue":"10","key":"3845_CR7","doi-asserted-by":"publisher","first-page":"e14493","DOI":"10.1111\/ijcp.14493","volume":"75","author":"MA Abdelrahman","year":"2021","unstructured":"Abdelrahman MA, Abdelrahim ME, Saeed H. Impact of different nebulisers\u2019 connections on aerosol therapy. Int J Clin Pract. 2021;75(10):e14493.","journal-title":"Int J Clin Pract"},{"issue":"9770","key":"3845_CR8","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1016\/S0140-6736(10)60926-9","volume":"377","author":"MB Dolovich","year":"2011","unstructured":"Dolovich MB, Dhand R. Aerosol drug delivery: developments in device design and clinical use. Lancet. 2011;377(9770):1032\u201345.","journal-title":"Lancet"},{"issue":"2","key":"3845_CR9","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1080\/17425247.2020.1712356","volume":"17","author":"A Ari","year":"2020","unstructured":"Ari A, Fink JB. Recent advances in aerosol devices for the delivery of inhaled medications. Expert Opin Drug Deliv. 2020;17(2):133\u201344.","journal-title":"Expert Opin Drug Deliv"},{"issue":"10","key":"3845_CR10","doi-asserted-by":"publisher","first-page":"745","DOI":"10.3760\/cma.j.issn.0578-1310.2013.10.006","volume":"51","author":"The Subspecialty Group of Respiratory Diseases, The Society of Pediatrics, Chinese Medical Association","year":"2013","unstructured":"The Subspecialty Group of Respiratory Diseases, The Society of Pediatrics, Chinese Medical Association. The editorial board, Chinese journal of pediatrics. Guidelines for management of community acquired pneumonia in children (the revised edition of 2013) (I). Chin J Pediatr. 2013;51(10):745\u201352. https:\/\/doi.org\/10.3760\/cma.j.issn.0578-1310.2013.10.006.","journal-title":"Chin J Pediatr"},{"issue":"10","key":"3845_CR11","doi-asserted-by":"publisher","first-page":"745","DOI":"10.3760\/cma.j.issn.0578-1310.2013.11.012","volume":"51","author":"The Subspecialty Group of Respiratory Diseases, The Society of Pediatrics, Chinese Medical Association","year":"2013","unstructured":"The Subspecialty Group of Respiratory Diseases, The Society of Pediatrics, Chinese Medical Association. The editorial board, Chinese journal of pediatrics. Guidelines for management of community acquired pneumonia in children (the revised edition of 2013) (II). Chin J Pediatr. 2013;51(10):745\u201352. https:\/\/doi.org\/10.3760\/cma.j.issn.0578-1310.2013.11.012.","journal-title":"Chin J Pediatr"},{"key":"3845_CR12","unstructured":"National Health and Family Planning Commission of the People\u2019s Republic of China. State Administration of Traditional Chinese Medicine of the People\u2019s Republic of China, Medical Department of the People\u2019s Liberation Army General Logistics Department. Guideline principles for clinical use of antibiotic (version 2015). [S]. Beijing, 2015. https:\/\/www.nhc.gov.cn\/yzygj\/c100068\/201508\/9f7136d6fb034339a7c9348c72a8a1fd\/files\/1732864152643_67691.pdf"},{"issue":"1","key":"3845_CR13","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.chest.2020.01.042","volume":"158","author":"AB Chang","year":"2020","unstructured":"Chang AB, Oppenheimer JJ, Irwin RS, CHEST Expert Cough Panel. Managing chronic cough as a symptom in children and management algorithms: CHEST guideline and expert panel report. Chest. 2020;158(1):303\u201329.","journal-title":"Chest"},{"issue":"6","key":"3845_CR14","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1378\/chest.13-0310","volume":"144","author":"KM Schmit","year":"2013","unstructured":"Schmit KM, Coeytaux RR, Goode AP, et al. Evaluating cough assessment tools: a systematic review. Chest. 2013;144(6):1819\u201326. https:\/\/doi.org\/10.1378\/chest.13-0310.","journal-title":"Chest"},{"issue":"11","key":"3845_CR15","first-page":"856","volume":"51","author":"Editorial board of Chinese Journal of Pediatrics","year":"2013","unstructured":"Editorial board of Chinese Journal of Pediatrics. Guidelines for management of community acquired pneumonia in children. Chin J Pediatr. 2013;51(11):856\u201362.","journal-title":"Chin J Pediatr"},{"issue":"8","key":"3845_CR16","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1517\/17425255.4.8.1119","volume":"4","author":"M Malerba","year":"2008","unstructured":"Malerba M, Ragnoli B. Ambroxol in the 21st century: Pharmacological and clinical update. Expert Opin Drug Metab Toxicol. 2008;4(8):1119\u201329.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"3845_CR17","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/BF00271364","volume":"44","author":"B Oosterhuis","year":"1993","unstructured":"Oosterhuis B, Storm G, Cornelissen PJ, Su CA, Sollie FA, Jonkman JH. Dose-dependent uricosuric effect of ambroxol. Eur J Clin Pharmacol. 1993;44:237\u201341.","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"3845_CR18","first-page":"71","volume":"63","author":"S Sundstr\u00f6m","year":"2009","unstructured":"Sundstr\u00f6m S, Ljungqvist B, Reinm\u00fcller B. Some observations on airborne particles in the critical areas of a blow-fill-seal machine. PDA J Pharm Sci Technol. 2009;63(1):71\u201380.","journal-title":"PDA J Pharm Sci Technol"},{"issue":"5","key":"3845_CR19","doi-asserted-by":"publisher","first-page":"614","DOI":"10.3109\/10837450.2011.557733","volume":"17","author":"A Amin","year":"2012","unstructured":"Amin A, Dare M, Sangamwar A, Bansal AK. Interaction of antimicrobial preservatives with blow-fill-seal packs: correlating sorption with solubility parameters. Pharm Dev Technol. 2012;17(5):614\u201324.","journal-title":"Pharm Dev Technol"},{"key":"3845_CR20","doi-asserted-by":"publisher","first-page":"117955061882193","DOI":"10.1177\/1179550618821930","volume":"12","author":"F Scaglione","year":"2019","unstructured":"Scaglione F, Petrini O. Mucoactive agents in the therapy of upper respiratory airways infections: fair to describe them just as mucoactive?? Clin Med Insights Ear Nose Throat. 2019;12:1179550618821930.","journal-title":"Clin Med Insights Ear Nose Throat"},{"key":"3845_CR21","doi-asserted-by":"crossref","unstructured":"Seagrave J, Albrecht HH, Hill DB, Rogers DF, Solomon G. Effects of guaifenesin, N-acetylcysteine, and ambroxol on MUC5AC and mucociliary transport in primary differentiated human tracheal-bronchial cells. Respir Res. 2012;13(1):98.","DOI":"10.1186\/1465-9921-13-98"},{"key":"3845_CR22","doi-asserted-by":"publisher","first-page":"175496","DOI":"10.1016\/j.ejphar.2023.175496","volume":"941","author":"D Saito","year":"2023","unstructured":"Saito D, Suzuki C, Tanaka S, Hosogi S, Kawaguchi K, Asano S, et al. Ambroxol-enhanced ciliary beating via voltage-gated Ca2\u2009+\u2009channels in mouse airway ciliated cells. Eur J Pharmacol. 2023;941:175496.","journal-title":"Eur J Pharmacol"},{"key":"3845_CR23","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.ejphar.2016.02.030","volume":"775","author":"SJ Zhang","year":"2016","unstructured":"Zhang SJ, Jiang JX, Ren QQ, Jia YL, Shen J, et al. Ambroxol inhalation ameliorates LPS-induced airway inflammation and mucus secretion through the extracellular signal-regulated kinase 1\/2 signaling pathway. Eur J Pharmacol. 2016;775:138\u201348.","journal-title":"Eur J Pharmacol"},{"issue":"3","key":"3845_CR24","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1080\/17425255.2019.1578748","volume":"15","author":"V Deretic","year":"2019","unstructured":"Deretic V, Timmins GS. Enhancement of lung levels of antibiotics by ambroxol and bromhexine. Expert Opin Drug Metab Toxicol. 2019;15(3):213\u20138.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"6","key":"3845_CR25","doi-asserted-by":"publisher","first-page":"106192","DOI":"10.1016\/j.ijantimicag.2020.106192","volume":"56","author":"M Alkotaji","year":"2020","unstructured":"Alkotaji M. Azithromycin and ambroxol as potential pharmacotherapy for SARS-CoV-2. Int J Antimicrob Agents. 2020;56(6):106192.","journal-title":"Int J Antimicrob Agents"},{"key":"3845_CR26","first-page":"700","volume":"50","author":"H Matthys","year":"2000","unstructured":"Matthys H, de Mey C, Carls C, Ry\u015b A, Geib A, Wittig T. Efficacy and tolerability of myrtol standardized in acute bronchitis. A multi-centre, randomised, double-blind, placebo-controlled parallel group clinical trial vs. cefuroxime and ambroxol. Arzneimittelforschung. 2000;50:700\u201311.","journal-title":"Arzneimittelforschung"},{"key":"3845_CR27","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1159\/000195274","volume":"51","author":"D Olivieri","year":"1987","unstructured":"Olivieri D, Zavattini G, Tomasini G, Daniotti S, Bonsignore G, Ferrara G, et al. Ambroxol for the prevention of chronic bronchitis exacerbations: long-term multicenter trial. Protective effect of ambroxol against winter semester exacerbations: a double-blind study versus placebo. Respiration. 1987;51:42\u201351.","journal-title":"Respiration"}],"container-title":["BMC Pulmonary Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-025-03845-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12890-025-03845-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-025-03845-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T19:36:21Z","timestamp":1757360181000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpulmmed.biomedcentral.com\/articles\/10.1186\/s12890-025-03845-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,8]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3845"],"URL":"https:\/\/doi.org\/10.1186\/s12890-025-03845-0","relation":{},"ISSN":["1471-2466"],"issn-type":[{"value":"1471-2466","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,8]]},"assertion":[{"value":"24 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments. This trial was approved by the Ethics Committee of Beijing Children\u2019s Hospital affiliated with Capital Medical University (the ethical approval number: [2013]-8-1). All participants or authorized surrogates would be given a detailed explanation of this trial. The guardian of these children voluntarily signed a written informed consent form, meanwhile, the children whose age more than 10 years old also required to sign by themself.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"382"}}